Orgenesis plans to reapply for Nasdaq listing after trading on OTCQX® Best Market

From GlobeNewswire: 2024-10-21 08:00:00

Orgenesis Inc. (NASDAQ: ORGS) announces plans to reapply for Nasdaq listing after being delisted due to failure to meet stockholders’ equity threshold. The company’s common stock will trade on the OTCQX® Best Market under the symbol “ORGS” in the interim. CEO Vered Caplan remains focused on advancing decentralized platform for cell and gene therapies to improve accessibility. Orgenesis believes its Decentralized Cell Processing platform can revolutionize the industry by providing cost-effective, scalable solutions. The company’s partnerships with hospitals and research institutions globally position Orgenesis for potential growth and value creation in the cell and gene therapy sector.



Read more at GlobeNewswire: Orgenesis Commences Trading on OTCQX® Best Market